X

Drug Profile

Research programme: RAS/MAPK protein degraders - Erasca

Alternative Names: ERAS-10; ERAS-10 therapeutics; Proteolytic cancer therapeutics - Erasca

Latest Information Update: 09 May 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Erasca
Class Antineoplastics
Mechanism of Action Proteolysis

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Cancer

Most Recent Events

31 Dec 2022 Erasca has patent pending for RAS/MAPK protein degraders
31 Dec 2022 Erasca has patent protection for RAS/MAPK protein degraders
02 Sep 2021 Early research in Cancer in USA (unspecified route) prior to September 2021 (Erasca pipeline, September 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com